CT-2103: emerging utility and therapy for solid tumours

Area of Science:

• Oncology
• Pharmacology
• Drug Delivery

Background:

• Paclitaxel is a widely used chemotherapy agent, but its efficacy can be limited by its administration vehicle (Cremophor EL) and associated toxicities.
• CT-2103 (XYOTAX) is a novel conjugate of paclitaxel to a polyglutamate polymer, designed to improve tumor targeting and drug release.
• The macromolecular nature of CT-2103 enhances its permeability and retention in tumor tissues, while its unique formulation avoids the need for Cremophor EL.

Purpose of the Study:

• To evaluate the pharmacokinetic, biodistribution, and antitumor activity of CT-2103 in preclinical models.
• To assess the safety and tolerability of CT-2103 in early-phase clinical trials.
• To investigate the efficacy of CT-2103 in patients with non-small cell lung carcinoma (NSCLC) and ovarian cancer.

Main Methods:

• Preclinical studies compared CT-2103 to unconjugated paclitaxel in terms of plasma and tumor pharmacokinetics and efficacy in various tumor models.
• Phase I clinical trials assessed the safety, tolerability, and maximum tolerated dose (MTD) of CT-2103, both as a single agent and in combination with carboplatin.
• Phase II and III clinical trials are ongoing to evaluate CT-2103 efficacy in NSCLC and ovarian cancer patients, comparing it against standard chemotherapy regimens.

Main Results:

• Preclinical studies demonstrated a >12-fold increase in the area under the curve for CT-2103 in plasma and tumor tissue compared to paclitaxel, with enhanced antitumor activity, including in paclitaxel-resistant models.
• Phase I trials indicated that CT-2103 is relatively well-tolerated, with acceptable toxicity at doses up to 225 mg/m(2) every 3 weeks. The MTD with carboplatin was 235 mg/m(2).
• Clinical activity has been observed in NSCLC and ovarian cancer, leading to ongoing Phase III trials comparing CT-2103 to paclitaxel in ovarian cancer maintenance therapy and Phase II trials comparing it to docetaxel in second-line NSCLC treatment.

Conclusions:

• CT-2103 exhibits a favorable pharmacokinetic profile and enhanced antitumor activity compared to conventional paclitaxel in preclinical settings.
• The agent demonstrates acceptable safety and tolerability in early clinical trials, suggesting a potential for improved therapeutic index.
• Ongoing clinical trials will further define the role of CT-2103 in the treatment of solid tumors, particularly NSCLC and ovarian cancer, potentially offering a new therapeutic option.